Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02948881 · ClinicalTrials.gov registry record · Phase 4
A Study To Assess The Quality Of Bone In Patients Taking Oral Ibandronate Versus Placebo
A Phase 4 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
NCT02948881 is a Phase 4 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 100 participants.
The verdict
NCT02948881, a Phase 4 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
Study Summary
The purpose of this study is to estimate the effect of oral Boniva (ibandronate sodium)taken once monthly versus placebo on bone quality and strength at the hip at one year.
Interventions
- DRUG ibandronate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2005-08 |
| Est. Completion | 2007-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02948881
The ClinicalTrials.gov registry entry for NCT02948881 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ibandronate is the first listed.
NCT02948881 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02948881 about?
NCT02948881 is a clinical study titled "A Study To Assess The Quality Of Bone In Patients Taking Oral Ibandronate Versus Placebo". The purpose of this study is to estimate the effect of oral Boniva (ibandronate sodium)taken once monthly versus placebo on bone quality and strength at the hip at one year.
What is the current status of trial NCT02948881?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2005-08. Estimated completion is 2007-07.
What interventions are being tested in trial NCT02948881?
The interventions under investigation include: ibandronate (DRUG).
Who is sponsoring clinical trial NCT02948881?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.